MA26660A1 - Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate. - Google Patents

Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate.

Info

Publication number
MA26660A1
MA26660A1 MA25684A MA25684A MA26660A1 MA 26660 A1 MA26660 A1 MA 26660A1 MA 25684 A MA25684 A MA 25684A MA 25684 A MA25684 A MA 25684A MA 26660 A1 MA26660 A1 MA 26660A1
Authority
MA
Morocco
Prior art keywords
propylcarbamate
phosphonooxy
aminophenyl
furanyl
tetrahydro
Prior art date
Application number
MA25684A
Other languages
English (en)
Inventor
Gordon Armitage Ian
David Searle Andrew
Singh Hardev
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26660A1 publication Critical patent/MA26660A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA25684A 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate. MA26660A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
MA26660A1 true MA26660A1 (fr) 2004-12-20

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25684A MA26660A1 (fr) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate.

Country Status (48)

Country Link
US (3) US6514953B1 (fr)
EP (2) EP1098898B1 (fr)
JP (1) JP3437553B2 (fr)
KR (1) KR100694721B1 (fr)
CN (1) CN1188422C (fr)
AP (1) AP2001002039A0 (fr)
AR (1) AR019388A1 (fr)
AT (1) ATE229964T1 (fr)
AU (1) AU766056B2 (fr)
BG (1) BG105253A (fr)
BR (1) BRPI9912156B8 (fr)
CA (1) CA2337857C (fr)
CO (1) CO5090836A1 (fr)
CZ (1) CZ300447B6 (fr)
DE (1) DE69904600T2 (fr)
DK (1) DK1098898T3 (fr)
DZ (1) DZ2845A1 (fr)
EA (1) EA003191B1 (fr)
EE (1) EE200100038A (fr)
ES (1) ES2189450T3 (fr)
GB (1) GB9815567D0 (fr)
GC (1) GC0000105A (fr)
GE (1) GEP20033030B (fr)
GT (1) GT199900111A (fr)
HK (1) HK1034261A1 (fr)
HR (1) HRP20010046A2 (fr)
HU (1) HU229700B1 (fr)
ID (1) ID28070A (fr)
IL (1) IL140824A (fr)
IS (1) IS5808A (fr)
JO (1) JO2114B1 (fr)
MA (1) MA26660A1 (fr)
MY (1) MY122323A (fr)
NO (1) NO329676B1 (fr)
NZ (1) NZ509291A (fr)
OA (1) OA11706A (fr)
PA (1) PA8477801A1 (fr)
PE (1) PE20000869A1 (fr)
PL (1) PL195736B1 (fr)
PT (1) PT1098898E (fr)
SK (1) SK285311B6 (fr)
SV (1) SV1999000096A (fr)
TN (1) TNSN99145A1 (fr)
TR (1) TR200100111T2 (fr)
TW (1) TWI245770B (fr)
WO (1) WO2000004033A1 (fr)
YU (1) YU3401A (fr)
ZA (1) ZA200100417B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
DK1222192T3 (da) * 1999-10-06 2008-10-20 Tibotec Pharm Ltd Hexahydrofuro-2,3-b furan-3-yl-N-3-(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino-1-benzyl-2-hydroxypropyl-carbamat som retroviral proteaseinhibitor
IL148820A0 (en) 1999-10-08 2002-09-12 Smithkline Beecham Corp Fab i inhibitors
WO2003088897A2 (fr) * 2001-04-06 2003-10-30 Affinium Pharmaceuticals, Inc. Inhibiteurs de fab i
CN1656109A (zh) * 2002-04-26 2005-08-17 吉里德科学公司 非核苷逆转录酶抑制剂
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
EP1608377B1 (fr) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Compositions comportant plusieurs agents antibiotiques, et leurs procedes de mise en oeuvre
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
WO2004096287A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Composes de phosphonate inhibiteurs de l'inosine monophosphate deshydrogenase
WO2004096285A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096286A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues de phosphonate antiviraux
EP1670448B1 (fr) * 2003-09-30 2007-11-21 Tibotec Pharmaceuticals Ltd. Sulfonamides inhibant le hcv
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
EP1678321A1 (fr) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Procedes et compositions permettant d'identifier des composes therapeutiques
WO2005063751A1 (fr) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Derives de carbovir et d'abacavir 4'-substitues et composes associes dotes d'une activite antivirale dirigee contre le vih et le vhc
JP5087406B2 (ja) 2004-06-04 2012-12-05 アフィニウム ファーマシューティカルズ， インク． 治療薬ならびにその製造方法および使用方法
ES2363160T3 (es) 2004-07-27 2011-07-22 Gilead Sciences, Inc. Conjugados de fosfonato nucelosidico como agentes anti-vih.
ES2537974T3 (es) 2004-11-26 2015-06-16 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
WO2008009122A1 (fr) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Dérivés d'acrylamide en tant qu'inhibiteurs de fab i
WO2008098374A1 (fr) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Sels, promédicaments et polymorphes d'inhibiteurs de fab 1
JP5448854B2 (ja) 2007-03-12 2014-03-19 ウェルズ ファーゴ バンク ナショナル アソシエイション オリゴマー−プロテアーゼ阻害剤複合体
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
WO2010115055A1 (fr) 2009-04-03 2010-10-07 Ocera Therapeutics, Inc. Acétate de phényle l-ornithine et ses procédés de fabrication
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
DK2440200T3 (en) 2009-06-08 2014-12-08 Ucl Business Plc Treatment of portal hypertension in the application of l-ornithinphenylacetat
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
EP2448949A1 (fr) 2009-06-30 2012-05-09 Ranbaxy Laboratories Limited Forme cristalline de fosamprénavir calcium
EP2477996A1 (fr) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Procédé pour préparer du fosamprénavir calcium
US20110165202A1 (en) * 2010-01-07 2011-07-07 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
ES2969969T3 (es) 2010-01-27 2024-05-23 Viiv Healthcare Co Combinaciones de dolutegravir y lamivudina para el tratamiento de la infección por VIH
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (fr) 2010-03-19 2011-09-22 Lupin Limited Sels d'ammonium, de calcium et de tris de fosamprénavir
WO2011158259A1 (fr) 2010-06-18 2011-12-22 Matrix Laboratories Ltd Nouveau procédé pour la préparation du (1s, 2r)-3-[[(4-aminophényl)sulfonyl] (isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate de (3s)-tétrahydrofurane-3-yle et ses sels pharmaceutiquement acceptables
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
NZ609191A (en) 2010-10-06 2015-06-26 Ocera Therapeutics Inc Methods of making l-ornithine phenyl acetate
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
WO2012085625A1 (fr) 2010-12-21 2012-06-28 Lupin Limited Procédé pour la préparation de fosamprénavir calcique et d'un intermédiaire utilisé dans sa préparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (fr) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Procédé de préparation de sulfonamides utiles en tant qu'inhibiteurs de protéase rétroviraux
IN2012DE00082A (fr) 2012-01-10 2015-05-01 Council Scient Ind Res
DK2861608T3 (da) 2012-06-19 2019-06-24 Debiopharm Int Sa Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
BR112017010761B1 (pt) 2014-11-24 2022-10-18 Ucl Business Plc Tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
WO2017031131A1 (fr) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Traitement et prévention de la perte musculaire au moyen de l-ornithine en combinaison avec au moins un parmi l'acétate de phényle et le butyrate de phényle
CN108778286A (zh) 2016-02-26 2018-11-09 德彪药业国际股份公司 用于治疗糖尿病足感染的药物
CA3063134A1 (fr) 2017-05-11 2018-11-15 Ocera Therapeutics, Inc. Procedes de fabrication de l-ornithine phenylacetate
WO2019027920A1 (fr) 2017-08-01 2019-02-07 Gilead Sciences, Inc. Formes cristallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement d'infections virales

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
TR200002402T2 (tr) * 1997-12-24 2001-01-22 Vertex Pharmaceuticals Incorporated Aspartil proteaz inhibitörü ön-ilaçlar.
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
EP1126847A1 (fr) * 1998-11-04 2001-08-29 PHARMACIA & UPJOHN COMPANY Methode destinee a ameliorer la pharmacocinetique du tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ES2295068T3 (es) * 1999-11-24 2008-04-16 MERCK & CO., INC. Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.

Also Published As

Publication number Publication date
EE200100038A (et) 2002-06-17
US20030096795A1 (en) 2003-05-22
JO2114B1 (en) 2000-05-21
PE20000869A1 (es) 2000-09-08
GEP20033030B (en) 2003-07-25
YU3401A (sh) 2005-06-10
MY122323A (en) 2006-04-29
AR019388A1 (es) 2002-02-13
KR100694721B1 (ko) 2007-03-15
EP1240903A3 (fr) 2003-02-12
EA003191B1 (ru) 2003-02-27
ATE229964T1 (de) 2003-01-15
DE69904600T2 (de) 2003-11-13
SK285311B6 (sk) 2006-10-05
NO20010282D0 (no) 2001-01-17
JP3437553B2 (ja) 2003-08-18
EP1098898A1 (fr) 2001-05-16
ID28070A (id) 2001-05-03
GT199900111A (es) 2001-01-05
GB9815567D0 (en) 1998-09-16
ZA200100417B (en) 2002-02-27
DK1098898T3 (da) 2003-04-07
CN1188422C (zh) 2005-02-09
HRP20010046A2 (en) 2002-02-28
AU766056B2 (en) 2003-10-09
US6514953B1 (en) 2003-02-04
CA2337857A1 (fr) 2000-01-27
IL140824A0 (en) 2002-02-10
HU229700B1 (en) 2014-05-28
SV1999000096A (es) 2000-07-06
PL345620A1 (en) 2002-01-02
CZ300447B6 (cs) 2009-05-20
CA2337857C (fr) 2011-01-25
EP1240903A2 (fr) 2002-09-18
OA11706A (en) 2005-01-13
EA200100053A1 (ru) 2001-08-27
GC0000105A (en) 2005-06-29
NO329676B1 (no) 2010-11-29
IS5808A (is) 2001-01-12
EP1098898B1 (fr) 2002-12-18
NO20010282L (no) 2001-03-07
BG105253A (en) 2001-12-29
HUP0103432A3 (en) 2003-01-28
CN1324363A (zh) 2001-11-28
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
BR9912156A (pt) 2001-04-10
IL140824A (en) 2004-09-27
PA8477801A1 (es) 2000-05-24
PL195736B1 (pl) 2007-10-31
AP2001002039A0 (en) 2001-03-31
TNSN99145A1 (fr) 2005-11-10
DE69904600D1 (de) 2003-01-30
WO2000004033A1 (fr) 2000-01-27
HUP0103432A2 (hu) 2002-04-29
CO5090836A1 (es) 2001-10-30
HK1034261A1 (en) 2001-10-19
TR200100111T2 (tr) 2002-02-21
AU5037999A (en) 2000-02-07
JP2003521447A (ja) 2003-07-15
ES2189450T3 (es) 2003-07-01
SK762001A3 (en) 2001-10-08
CZ2001219A3 (cs) 2001-07-11
TWI245770B (en) 2005-12-21
BRPI9912156B1 (pt) 2016-07-26
BRPI9912156B8 (pt) 2021-05-25
DZ2845A1 (fr) 2003-12-01
PT1098898E (pt) 2003-04-30
NZ509291A (en) 2003-05-30

Similar Documents

Publication Publication Date Title
MA26660A1 (fr) Calcium (3s) tetrahydro-3-furanyl (1s,2r)-3- [[ ( (4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2 (phosphonooxy) propylcarbamate.
DZ2740A1 (fr) Catalyseurs de polymésation.
DZ2738A1 (fr) Catalyseurs de polymérisation.
ITMI982247A0 (it) Procedimento per impermeabilizzare la pelle ottenuta mediante tale procedimento
BR9603540A (pt) n-metil-n-((1s)-2-((3s)-3-hidróxl-pirrolidin-1-il)etil)-2,2-difenilacetamida
AU5818100A (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzy -2-(phosphonooxy)propylcarbamate
FR2763498B1 (fr) Endoscope, en particulier mediastinoscope
SI1098898T1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
ES1047984Y (es) Corchete de ortodoncia.
ES1033492Y (es) Mojon de limitacion vial, amovible.
ES1036075Y (es) Consola.
IT1303333B1 (it) Sottopiede per calzature.
HN1999000113A (es) (3s) tetrahidro - 3 - funaril (15, 2r) - 3 - [[4 - aminofenil) sulfonil)] (isobutil) amino] - 1 - bencil - 2 (fosfonooxi) propilcarbamato de calcio.
ITBO980069A0 (it) Piattaforma rotante per autoveicoli.
ES1030098Y (es) Tapa-casquillo nivelador, para somieres de ballestas.
ES1041422Y (es) Dispositivo emparejador de unidades de calzado.
KR950024792U (ko) 차량용 엘. 피. 지 캡(l. p. g cap)
ITBO970012A0 (it) Metodo per la formazione distrati di sigarette.
ES1039039Y (es) Dardo de ventosas para juego de diana.
ES1036214Y (es) Sillita-carrito de paseo-mochila, para muñecos.
IT245874Y1 (it) Sostegno-espositore per calzature.
ES1040568Y (es) Instrumento de escritura.
ES1039379Y (es) Bigudi retenedor de humedad.
ITBO970443A0 (it) Tovagliolino mappa per parco giochi.
ES1041310Y (es) Depresor lingual.